BioSpace News Archive

AI-driven in silico patients used to accurately identify types of immune responses in head and neck squamous cell carcinoma and non-small cell lung cancer

NK AWS-S200™ Performs Difficult Intubations in Less Than Half the Time of Other Devicesi

Biosight Ltd ., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced that it has entered into a clinical trial agreement with the French Study Group of the European Myelodysplastic Syndromes (MDS) Cooperative Group (EMSCO) led by Dr. Pierre Fenaux, the Groupe Francophone des Myélodysplasies (GFM). GFM is a non-profit organization comprised of most French he

NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the results from its Phase 3 study of IV tramadol in patients undergoing bunionectomy have been published in the peer-reviewed journal, Pain and Therapy. The objective of this Phase 3 study was to compare the analgesic benefit and tolerability of two doses of IV tramadol (50 mg and 25 m

One in three people develop bunions, and two-thirds are women

New Video Series and Digital Course Feature Interactive Content for Those Living with ADHD and Their Parents and Caregivers

Today the K-cosmeceutical company Dermafirm USA, Inc., the U.S. arm of South Korea’s Dermafirm Inc., is officially announcing its U.S. expansion

Kepley BioSystems filed the second of two recent patents describing novel approaches to protective applications addressing the Coronavirus pandemic, as well as increasing antimicrobial resistance threats. Kepley researchers have invented a method to permanently infuse a substrate with antimicrobial functional fullerenes. Appli

Neogen Corporation (NASDAQ: NEOG) announced today that revenues for the fourth quarter of its 2020 fiscal year, which ended May 31 , were $109,074,000 , compared to $109,762,000 the prior year quarter. Revenues for the company for the full fiscal year were $418,170,000 , compared to the prior year’s $414,186,000 . Fourth

University TMS, a mental health facility specializing in advanced treatments for neurological and psychiatric disorders, is now offering BrainsWay’s Deep Transcranial Magnetic Stimulation for major depressive disorder and obsessive-compulsive disorder.